By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Verinata Health today said that it has entered into a three-year supply deal with Illumina, under which it will purchase sequencing instruments and consumables for use in commercializing its prenatal diagnostics offerings.

Verinata is developing tests for detecting multiple aneuploidies. The San Carlos, Calif.-based firm said that in addition to the supply deal it will collaborate with Illumina on gaining regulatory approval for the testing service.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.